ECSP12011604A - Diferenciación de células madre mesenquimales - Google Patents

Diferenciación de células madre mesenquimales

Info

Publication number
ECSP12011604A
ECSP12011604A ECSP12011604A ECSP12011604A EC SP12011604 A ECSP12011604 A EC SP12011604A EC SP12011604 A ECSP12011604 A EC SP12011604A EC SP12011604 A ECSP12011604 A EC SP12011604A
Authority
EC
Ecuador
Prior art keywords
mesenquimal
differentiation
mother cells
mother
cells
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Kristen Johnson
Lori Jennings
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011604(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of ECSP12011604A publication Critical patent/ECSP12011604A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ECSP12011604 2009-07-14 2012-01-13 Diferenciación de células madre mesenquimales ECSP12011604A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14

Publications (1)

Publication Number Publication Date
ECSP12011604A true ECSP12011604A (es) 2012-06-29

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011604 ECSP12011604A (es) 2009-07-14 2012-01-13 Diferenciación de células madre mesenquimales

Country Status (30)

Country Link
US (4) US9139633B2 (enExample)
EP (1) EP2453921B1 (enExample)
JP (1) JP5602850B2 (enExample)
KR (3) KR20180000337A (enExample)
CN (2) CN102625830B (enExample)
AU (1) AU2010273570B2 (enExample)
BR (1) BR112012000914B8 (enExample)
CA (1) CA2767826C (enExample)
CL (1) CL2012000091A1 (enExample)
CO (1) CO6491059A2 (enExample)
CR (1) CR20120024A (enExample)
CU (1) CU24042B1 (enExample)
EA (1) EA023073B1 (enExample)
EC (1) ECSP12011604A (enExample)
ES (1) ES2541217T3 (enExample)
GT (1) GT201200011A (enExample)
IL (2) IL217383A (enExample)
IN (1) IN2012DN00572A (enExample)
MA (1) MA33423B1 (enExample)
MX (1) MX2012000707A (enExample)
MY (1) MY160951A (enExample)
NZ (1) NZ597306A (enExample)
PE (2) PE20120570A1 (enExample)
PL (1) PL2453921T3 (enExample)
PT (1) PT2453921E (enExample)
SG (1) SG177318A1 (enExample)
TN (1) TN2011000655A1 (enExample)
UA (1) UA104031C2 (enExample)
WO (1) WO2011008773A2 (enExample)
ZA (1) ZA201200078B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
CN109996082B (zh) 2011-11-08 2022-01-25 韩国电子通信研究院 用于共享候选者列表的方法和装置
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
AU2014236719B2 (en) 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
MY186570A (en) 2014-05-13 2021-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
CN104840486A (zh) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 一种组合物及其应用、制剂
MX2018010401A (es) 2016-03-03 2019-03-06 Regeneron Pharma Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3.
CN109963579A (zh) * 2016-11-14 2019-07-02 诺华股份有限公司 用于治疗软骨损伤和关节炎的方法和组合物
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
JP7471291B2 (ja) 2018-12-06 2024-04-19 ノバルティス アーゲー 関節損傷を治療するための軟骨形成を誘導するための５－ヒドロキシ－７－オキサビシクロ［２．２．１］ヘプタン－２－カルボキサミド誘導体
ES2965684T3 (es) 2018-12-06 2024-04-16 Novartis Ag Derivados de 6-hidroxi-8-oxatriciclo[3.2.1.02,4]octano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
CN109432128A (zh) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 牙髓间充质干细胞在银屑病治疗中的应用
KR102246582B1 (ko) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 올리고펩타이드를 이용한 줄기세포의 연골세포로의 분화 유도 방법
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (ja) * 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ９７個のヒト分泌タンパク質
WO1999067382A2 (en) 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
ATE368110T1 (de) * 1999-07-20 2007-08-15 Genentech Inc Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030144498A1 (en) * 2000-10-16 2003-07-31 Audrey Goddard TIE ligand homologues
CA2425145C (en) * 2000-10-16 2011-08-30 Genentech, Inc. Methods of treatment using wisp polypeptides
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
ES2429034T3 (es) * 2001-11-16 2013-11-12 Genentech, Inc. Uso de antagonistas de ANGPTL3 para el tratamiento de enfermedades hepáticas
KR100974843B1 (ko) * 2002-09-09 2010-08-11 넥타르 테라퓨틱스 수용성 중합체 알카날
US20060166214A1 (en) * 2003-03-10 2006-07-27 Yukio Kato Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
JP3979372B2 (ja) 2003-09-26 2007-09-19 ブラザー工業株式会社 画像処理装置、画像処理方法及び画像処理プログラム
WO2006002152A1 (en) * 2004-06-21 2006-01-05 The Cleveland Clinic Foundation Ccr ligands for stem cell homing
EP1863340A2 (en) 2005-03-11 2007-12-12 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
JP5139271B2 (ja) 2005-05-24 2013-02-06 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 培養した造血幹細胞を拡大しかつ分析する方法
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
JP2010525836A (ja) * 2007-05-04 2010-07-29 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ヒト造血幹細胞のｅｘｖｉｖｏ増殖
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
PT2453921E (pt) * 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
UY35368A (es) 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation

Also Published As

Publication number Publication date
US20120177644A1 (en) 2012-07-12
WO2011008773A3 (en) 2011-08-25
CN105601728B (zh) 2020-01-10
WO2011008773A2 (en) 2011-01-20
KR20180000337A (ko) 2018-01-02
CO6491059A2 (es) 2012-07-31
BR112012000914A2 (pt) 2017-08-08
EA201200118A1 (ru) 2012-09-28
US10064918B2 (en) 2018-09-04
HK1164169A1 (en) 2012-09-21
CN102625830A (zh) 2012-08-01
MA33423B1 (fr) 2012-07-03
TN2011000655A1 (en) 2013-05-24
BR112012000914B8 (pt) 2021-05-25
CN105601728A (zh) 2016-05-25
KR20120029472A (ko) 2012-03-26
BR112012000914B1 (pt) 2021-04-06
EA023073B1 (ru) 2016-04-29
IL217383A (en) 2016-08-31
PT2453921E (pt) 2015-09-25
MX2012000707A (es) 2012-03-21
JP5602850B2 (ja) 2014-10-08
US9139633B2 (en) 2015-09-22
NZ597306A (en) 2014-03-28
CU20120007A7 (es) 2013-02-26
PL2453921T3 (pl) 2015-11-30
KR20160015403A (ko) 2016-02-12
US10555990B2 (en) 2020-02-11
CU24042B1 (es) 2014-11-27
JP2012533549A (ja) 2012-12-27
EP2453921B1 (en) 2015-05-27
ZA201200078B (en) 2013-01-30
AU2010273570A1 (en) 2012-02-02
CN102625830B (zh) 2016-03-02
CR20120024A (es) 2012-06-11
AU2010273570B2 (en) 2014-07-03
BR112012000914A8 (pt) 2017-12-19
IL217383A0 (en) 2012-02-29
IL247310B (en) 2018-04-30
CA2767826C (en) 2015-11-24
SG177318A1 (en) 2012-03-29
EP2453921A2 (en) 2012-05-23
EP2453921A4 (en) 2012-12-19
MY160951A (en) 2017-03-31
US20200108122A1 (en) 2020-04-09
PE20120570A1 (es) 2012-05-19
KR101590834B1 (ko) 2016-02-12
CL2012000091A1 (es) 2012-10-26
UA104031C2 (uk) 2013-12-25
PE20160507A1 (es) 2016-05-20
CA2767826A1 (en) 2011-01-20
IN2012DN00572A (enExample) 2015-06-12
GT201200011A (es) 2013-12-10
US20190000922A1 (en) 2019-01-03
ES2541217T3 (es) 2015-07-16
US20160213748A1 (en) 2016-07-28
US11241482B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
CR20120024A (es) Diferenciación de células madre mesenquimales
CO6950482A2 (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
BR112013016535A2 (pt) extratos vegetais para o tratamento e prevenção de infecções
CL2015002301A1 (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c.
BR112013007231A2 (pt) ''processo para tratamento de efluente e processo para tratamento de uma água servida''
CR20140576A (es) Sintesis de compuestos heterociclicos
BRPI1014759A2 (pt) composto útil para o tratamento de doenças degenerativas e inflamatórias
BR112013024401A2 (pt) métodos e composições para o tratamento do transtorno do déficit de atenção
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
DK2588154T3 (da) Sammensætning omfattende calciumphosphat, sulfatpulvere eller dmb anvendt i behandlingen af degenerative knogletilstande
CO7020867A2 (es) Formulaciones de anticuerpo y metodos
CU20140025A7 (es) Pirimidinas anilladas sustituidas
CO6930356A2 (es) Compuestos inhibidores de metaloenzimas
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
BR112012018986A2 (pt) sistemas e métodos para redução de lodos produzidos por estações de tratamento de águas residuais
BRPI1009920A2 (pt) composições bacterianas para profilaxina e tratamento de doença degenerativa.
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
BR112013004165A2 (pt) métodos para o tratamento ou profilaxia da trombose ou embolia
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas